Redmile Group LLC 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-07-27 5:15 pm Sale | 2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 145,611 6.600% | -5,917 (-3.90%) | Filing |
| 2023-02-14 4:21 pm Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 151,528 6.900% | -64,550 (-29.87%) | Filing |
| 2022-02-14 5:07 pm Purchase | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 216,078 9.900% | 6,295 (+3.00%) | Filing |
| 2021-02-16 4:10 pm Purchase | 2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 209,783 9.900% | 209,783 (New Position) | Filing |